We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA ISSUES DRAFT GUIDANCE FOR DRUG STUDIES WITH PREGNANT WOMEN
FDA ISSUES DRAFT GUIDANCE FOR DRUG STUDIES WITH PREGNANT WOMEN
October 29, 2004
The FDA hopes a draft guidance for designing and conducting pharmacokinetic (PK) studies in pregnant women will stimulate R&D of appropriate treatments for such patients.